Micreos

Selective

Designed to target specific harmful bacterial pathogens.

Powerful

Potent activity, even against resistant strains and biofilms.

Resistance Resilient

Engineered to overcome pathogens’ resistance mechanisms.

Transformative

Unlocking new treatment paradigms for diseases with high unmet medical need.

About us

Reimagining how disease-driving pathogens are treated.

MICREOS is a Swiss-based biotechnology company pioneering a new class of precision biologics designed to selectively eliminate disease-driving pathogens and restore the biological balance essential to human health.

Through a long-standing collaboration with ETH Zürich and with deep expertise in microbiology, protein engineering, and therapeutics development, we are advancing our proprietary engineered endolysin platform with broad potential across dermatology, oncology, infectious diseases, and other therapeutic areas where harmful pathogens drive disease, amplify inflammation, or impair patients’ healing and recovery.

We believe the future of care lies in precision medicines—targeting what drives disease while protecting what keeps us healthy.

Micreos R&D Technology Center, Wädenswil, Zurich

STARTING WITH

Atopic Dermatitis.

Atopic Dermatitis (AD) is associated with a profound imbalance in the skin microbiome.

A compromised skin barrier creates conditions that enable the overgrowth of Staphylococcus aureus, a harmful pathogen closely associated with inflammation, disease severity, and recurrent flares.

Conventional therapies fail to selectively address this underlying microbial imbalance.

Our engineered endolysins are designed to selectively eliminate Staphylococcus aureus while preserving the healthy microbiome that protects the skin.

Why this matters in Atopic Dermatitis

S. aureus Overgrowth

Over-colonization disrupts the skin microbiome and is associated with increased inflammation and disease severity.

Barrier Disruption

Microbial imbalance and toxin production further weaken the skin barrier and exacerbate symptoms.

Cycle of Flares

This vicious cycle leads to chronic inflammation, intense itch, and recurrent flares.

By selectively eliminating S. aureus, we aim to break the cycle and restore biological balance.

* Patient benefits hypothesized from selective elimination of S. aureus and restoration of biological balance. To be evaluated in future clinical studies.

One Solution.
Broad Potential.

A platform technology with potential across multiple indications, beyond our core focus in Atopic Dermatitis.

Leadership team

Experienced leaders.
Driven by purpose.

Our team combines deep scientific expertise, drug development experience, and a shared commitment to transforming patient care.

Matt Regan

Chief Executive Officer, Director

View profile

Matt is CEO and Board Member of MICREOS and has led the company since October 2021.

Matt brings over 30 years of pharmaceutical leadership experience across seven countries, spanning the healthcare value chain with global companies including Abbott, AbbVie, and Novo Nordisk.

Matthew Dunne

chief development & science officer

View profile

Matthew joined MICREOS in April 2022 and serves as Chief Development & Science Officer.

Matthew is an internationally recognized expert with over 15 years of experience in research, genetic engineering, and protein-based antimicrobial development, including senior research leadership at ETH Zurich.

Martin Vlasaty

Chief Financial Officer

View profile

Martin leads Finance at MICREOS, a role he has held since December 2022.

Martin brings over 13 years of finance leadership experience from Roche / Genentech, bluebird bio, and Arena Pharmaceuticals, with a track record of building and scaling finance, business operations, and corporate governance.

Meet the Micreos R&D team